This trial is active not recruiting!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
2Find
3Review
4Get in touch
More info
You can access this
clinical trial
if you have
Bone Metastases, Castrate-resistant Prostate Cancer, Recurrent Prostate Cancer or Stage IV Prostate Cancer
and you are
2
This is a second phase trial assessing
efficacy and side effects of the new treatment.
Show me locations

The purpose

This study is being done to help researchers understand more about prostate cancer that has spread to the bones by using the newest magnetic resonance imaging (MRI) techniques and to better understand the effect of an experimental drug called XL184 (or cabozantinib) on bone disease. The other purposes of the study are to better understand the effect of XL184 on prostate cancer progression, bone pain, and on any cancer cells that patients may have circulating within the blood (called circulating tumor cells)

Provided treatments

  • Drug: cabozantinib
  • Other: laboratory biomarker analysis
  • Procedure: magnetic resonance imaging
Tris trial is registered with FDA with number: NCT01599793. The sponsor of the trial is University of Chicago and it is looking for 17 volunteers for the current phase.
Official trial title:
A Phase II Study of MRI Based Functional Imaging for the Evaluation of Bone Metastasis in Men With Castrate Resistant Prostate Cancer Receiving XL184